CSL has been Malaysia’s national fractionator of plasma-derived therapies since 1991.
Today, the Malaysian Ministry of Health continues to choose CSL Biotherapies as its national plasma fractionator. Regulated by the Therapeutic Goods Administration, a regulator held in high regard worldwide, and the National Pharmaceutical Control Bureau at the Ministry of Health, CSL Biotherapies and the Malaysian National Blood Centre (Pusat Darah Negara) ensure that the blood and plasma donations made voluntarily by people living in Malaysia continue to deliver the benefits that toll fractionation provides – a sustainable, reliable and high quality source of plasma-derived therapies, developed to treat serious medical conditions including immunodeficiency disorders, a range of haematological and neurological disorders, haemophilia, and trauma.
Blood and plasma donated by Malaysia’s donors is fractionated into four plasma-derived therapies at CSL Biotherapies' unique, purpose-built, chromatographic plasma fractionation facility, located at Broadmeadows in Victoria, Australia. For more information about these products, please refer to the table below.
